ALK-Abello AS (ALK B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
37
About the Report
About the Report
Summary
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK's research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company's products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.
ALK-Abello AS (ALK B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
ALK-Abello AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ALK-Abello AS, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alk Abello Enters into Co-Marketing Agreement with BioCSL 11
ALK-Abello Enters into Agreement with Seqirus 12
ALK-Abello Expands Partnership with Abbott Labs 13
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15
Licensing Agreements 16
Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16
Equity Offering 17
ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17
ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18
Center Labs to Raise USD96 Million in Private Placement of Shares 19
Center Labs to Raise Funds through Private Placement of Shares 20
ALK-Abello AS-Key Competitors 21
ALK-Abello AS-Key Employees 22
ALK-Abello AS-Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 25
Financial Announcements 25
Aug 15, 2018: ALK-Abello: Six-month interim report (Q2) 2018 25
May 04, 2018: ALK Releases Three-month interim report (Q1) 2018 26
Feb 06, 2018: ALK releases its annual report 2017 27
Nov 10, 2017: ALK-Abello: Nine-month interim report (Q3) 2017 28
Aug 16, 2017: ALK-Abello: Six-month interim report (Q2) 2017 29
Aug 16, 2017: ALK: Six-month interim report (Q2) 2017 30
May 09, 2017: ALK-Abello Announces Three-month interim report (Q1) 2017 31
Feb 07, 2017: ALK releases its annual report 2016 32
Corporate Communications 33
Nov 03, 2017: ALK appoints Soren Jelert as new Chief Financial Officer 33
Jul 31, 2017: Management change at ALK 34
Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 35
Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Figure
List of Figures
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
ALK-Abello AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ALK-Abello AS, Deals By Therapy Area, 2012 to YTD 2018 8
ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alk Abello Enters into Co-Marketing Agreement with BioCSL 11
ALK-Abello Enters into Agreement with Seqirus 12
ALK-Abello Expands Partnership with Abbott Labs 13
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15
Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16
ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17
ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18
Center Labs to Raise USD96 Million in Private Placement of Shares 19
Center Labs to Raise Funds through Private Placement of Shares 20
ALK-Abello AS, Key Competitors 21
ALK-Abello AS, Key Employees 22
ALK-Abello AS, Subsidiaries 23
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.